Linked Life Data

17943799

Source:http://linkedlifedata.com/resource/pubmed/id/17943799

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2007-10-18
pubmed:abstractText
Rituximab has been shown to improve response rates and progression free survival when added to chemotherapy in patients with indolent and mantle cell lymphoma. However, the impact of R on overall survival (OS) when given in combination with chemotherapy (R-chemo) has remained unclear so far.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1469-493X
pubmed:author
pubmed:issnType
Electronic
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
CD003805
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.
pubmed:affiliation
Univerisity Hospital Cologne, Cochrane Haematological Malignancies Group - Department of Internal Medicine 1, Kerpener Str 62, Köln (Cologne), Germany, D 50924. Holger.Schulz@uni-koeln.de
pubmed:publicationType
Journal Article, Review, Meta-Analysis